In conclusion, our data argue in favor of an increased risk of death in AML and MM patients with type 2 diabetes mellitus using SGLT2 inhibitors, even when accounting for a variety of metabolic covariates, including chronic kidney disease and congestive heart failure. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.